BACKGROUND AND PURPOSE: Proton MR spectroscopy has revealed impaired neuronal integrity in the motor cortex of patients with amyotrophic lateral sclerosis (ALS). We hypothesized that the N-acetylaspartate (NAA)-creatine (Cr) ratios in the motor cortex and adjacent brain could reflect the therapeutic effectiveness of gabapentin (GBP) treatment in ALS. METHODS: Eight patients with ALS underwent MR spectroscopy before and 26.5 days +/- 8.8 after starting GBP. In 10 patients with ALS who were not treated with GBP, paired spectra were obtained 21.4 days +/- 7.2 apart. Fourteen healthy subjects underwent a single MR spectroscopic examination. The NAA/Cr ratio was measured in the precentral gyrus, the postcentral gyrus, the superior parietal lobule, the supplementary motor area, and the premotor cortex. RESULTS: The NAA/Cr ratio was decreased in the precentral and postcentral gyri of patients with ALS compared with healthy controls. In those with ALS, the change in the NAA/Cr ratio was not different between treated patients and untreated patients in any of the regions studied. CONCLUSION: No improvement in neuronal integrity was detected in motor and nonmotor cerebral regions after GBP treatment. This result agrees with that of prior investigations showing the equivocal clinical effectiveness of GBP for ALS and supports the validity of the NAA/Cr ratio as a surrogate of therapeutic effectiveness.
BACKGROUND AND PURPOSE: Proton MR spectroscopy has revealed impaired neuronal integrity in the motor cortex of patients with amyotrophic lateral sclerosis (ALS). We hypothesized that the N-acetylaspartate (NAA)-creatine (Cr) ratios in the motor cortex and adjacent brain could reflect the therapeutic effectiveness of gabapentin (GBP) treatment in ALS. METHODS: Eight patients with ALS underwent MR spectroscopy before and 26.5 days +/- 8.8 after starting GBP. In 10 patients with ALS who were not treated with GBP, paired spectra were obtained 21.4 days +/- 7.2 apart. Fourteen healthy subjects underwent a single MR spectroscopic examination. The NAA/Cr ratio was measured in the precentral gyrus, the postcentral gyrus, the superior parietal lobule, the supplementary motor area, and the premotor cortex. RESULTS: The NAA/Cr ratio was decreased in the precentral and postcentral gyri of patients with ALS compared with healthy controls. In those with ALS, the change in the NAA/Cr ratio was not different between treated patients and untreated patients in any of the regions studied. CONCLUSION: No improvement in neuronal integrity was detected in motor and nonmotor cerebral regions after GBP treatment. This result agrees with that of prior investigations showing the equivocal clinical effectiveness of GBP for ALS and supports the validity of the NAA/Cr ratio as a surrogate of therapeutic effectiveness.
Authors: S Vielhaber; J Kaufmann; M Kanowski; M Sailer; H Feistner; C Tempelmann; C E Elger; H J Heinze; W S Kunz Journal: Exp Neurol Date: 2001-12 Impact factor: 5.330
Authors: R G Miller; D Moore; L A Young; C Armon; R J Barohn; M B Bromberg; W W Bryan; D F Gelinas; M C Mendoza; H E Neville; G J Parry; J H Petajan; J M Ravits; S P Ringel; M A Ross Journal: Neurology Date: 1996-12 Impact factor: 9.910
Authors: W Block; J Karitzky; F Träber; C Pohl; E Keller; R R Mundegar; R Lamerichs; H Rink; F Ries; H H Schild; F Jerusalem Journal: Arch Neurol Date: 1998-07
Authors: F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi Journal: AJNR Am J Neuroradiol Date: 2010-04-01 Impact factor: 3.825
Authors: Andrea Diana; Rita Pillai; Paolo Bongioanni; Aidan G O'Keeffe; Robert G Miller; Dan H Moore Journal: Cochrane Database Syst Rev Date: 2017-01-09
Authors: Stefan Sivák; Michal Bittšanský; Egon Kurča; Monika Turčanová-Koprušáková; Milan Grofik; Vladimír Nosál'; Hubert Poláček; Dušan Dobrota Journal: Neuroradiology Date: 2010-04-06 Impact factor: 2.804